Abbott to collaborate with Cadrenal on anticoagulant tecarfarin
by
Contributor since / Followers
Contributor since / Followers
8 months ago
Hailshadow
- Abbott Laboratories (NYSE:ABT) has agreed to collaborate with Cadrenal Therapeutics (NASDAQ:CVKD) on the latter’s pivotal study for its anticoagulant candidate tecarfarin.
- The oral blood thinner is aimed at patients with implanted cardiac devices and those with rare cardiovascular conditions.
- The trial will investigate tecarfarin in patients with recently implanted left ventricular assist devices. Abbott makes the only LVAD available in the U.S., the HeartMate 3.
- Tecfarin also has Orphan Drug status from the U.S. FDA.